Across TCGA pan-cancer cohorts, LINC02272 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02272’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02272 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02272 is over-expressed in tumor.
BRCA are the cancer types where LINC02272 tumor–normal differential expression is most reproducible.